Vav3 is a key modulator of GTP-hydrolases of the Rho/Rac family, which are crucially involved in cell proliferation. Vav3 is alternatively spliced in full-length Vav3-alpha and N-terminal truncated Vav3.1 lacking its self-regulatory domains. The aim of our study was to estimate the clinical impact of Vav3 and all other Vav family members in ovarian cancer. Purification of a stem-cell like side-population (SP) from ovarian cancer cell lines was performed by flow cytometry/FACS. Differences in gene expression between SP and NSP were assessed by Gene Array analysis and confirmed by RT-PCR and immunoblot. In addition, Vav mRNA expression was determined in 150 epithelial ovarian cancers. Clinicopathological parameters, platinum-sensitivity and survival were analyzed and associated with Vav expression. SP fractions of ovarian cancer cell lines exhibited marked overexpression of Vav3.1 (p < 0.001). Vav1 and Vav2 did not prove to be of clinicopathologic relevance in ovarian cancer. High Vav3.1 expression correlated with higher FIGO stage and residual disease. Furthermore, Vav3.1 overexpression was associated with poor progression-free (HR 5 2.820, p 5 0.0001) and overall survival (HR 5 2.842, p 5 0.0001). Subgroup analyses revealed an impact of Vav3.1 on survival in Type-II but not in Type-I cancers. Notably, platinum-refractory cancers showed marked overexpression of Vav3.1 compared to other subsets of platinum-sensitivity (15.848 vs. 6.653, p 5 0.0001). In conclusion, Vav3.1 is over-expressed in stem-cell like SP fractions and is clinically relevant in the pathophysiology of ovarian cancer. The N-terminal truncated Vav3.1 may be decisively involved in mechanisms causing genuine multi-drug resistance.
Introduction
GTP-hydrolases of the Rho/Rac family are crucially involved in the promotion of cytoskeletal structures that contribute to changes in cell shape and motility, activation of lipid and protein kinase cascade, and the expression of genes required for differentiation, development and cell proliferation. 1 The activity of these proteins was shown to be involved in transformation and oncogenesis, either by triggering the metastatic potential of transformed cells or by serving as ancillary factors that contribute to the transforming activity of oncoproteins such as Ras. 2 Rho/Rac activity is regulated by different classes of proteins. GTPase activating proteins (GAPs) induce the intrinsic GTP-hydrolase activity of Rho/Rac yielding to dephosphorylation of GTP to GDP and subsequent inactivation of Rho/Rac. In addition, guanine nucleotide dissociation inhibitors (GDIs) are keeping GDP bound GTP-hydrolases in an inactive status. 3, 4 In contrary, GDP/GTP exchange is enhanced by regulatory molecules known as guanine exchange factors (GEFs). 2 Within the latter group the Vav family of proteins has been best characterized: In fact, activation of GTPhydrolases is mediated by a rapid and transient phosphorylation on tyrosine residues of Vav, leading to an increase in its GDP-GTP exchange activity toward Rho/Rac proteins. However, tyrosine phosphorylation also regulates other functions of these proteins, such as the association with other tyrosine kinases or adapter molecules and the formation of heteromolecular complexes. In this context, it has been shown that decomposition of the normal activation-deactivation cycle of some members of the Vav family results in severe alteration in cell behavior, such as tumorigenesis and acquisition of metastatic properties. 5, 6 While Vav1 represents a hematopoietic cell specific signal transducer protein, Vav2 and Vav3 show expression in a wide variety of tissues. 6 All Vav proteins contain several characteristic structural motifs enabling their function as signal transducers: The GEF activity toward Rho family GTPases is mainly mediated by their central Dbl homology region, whereas a pleckstrin homology (PH) domain interacts with polyphosphoinositides; the C-terminal Src-homology 2 (SH2) domain flanked by two Src-homology 3 (SH3) domains mediates interaction with phosphorylated tyrosine containing proteins. Moreover, the actin-binding "calponinhomology" (CH) domain and an acidic-rich (Ac) region are highly conserved at the N-terminus of the Vav protein. In fact, Vav proteins are the only known Rho GEFs that combine in the same protein the DH/PH motifs, which reflects their main function as Rho/Rac protein modulators, and the SH2/SH3 domains, which reflect their pivotal role in signal transduction. 7, 8 To date there are two known Vav3 isoforms produced by alternative splicing and a third transcript thought to be derived by alternative promoter usage: the 847 amino acid alpha isoform (canonical sequence) and the 753 amino acid beta isoform show a 58% homology with Vav1 and Vav2; conversely, the N-terminal truncated 287 amino acid isoform Vav3.1 is derived from the unique exon 18 and contains the C-terminal SH3-SH2-SH3 domain only. 9, 10 While the exact role of the truncated Vav3.1 isoform is unknown, full-length Vav3-alpha was shown to be involved in tumorigenesis and prognosis in a variety of tumors, including breast, prostate and gastric cancer. [11] [12] [13] [14] In addition, Vav3 has been shown to play a central role in the angiogenic response within the tumor microenvironment. 15 The suggested pivotal role of Vav3 in tumorigenesis and tumor progression led us to investigate the function and clinical relevance of distinct Vav isoforms in ovarian cancer.
Material and Methods

Patients
As training set tissue samples from patients with invasive, epithelial ovarian cancer were collected during primary debulking surgery at the Department of Gynecology in Innsbruck between 2000 and 2010 (N 5 150). Our patient cohort represented 65% of the total of patients (N 5 236) who underwent primary surgery for ovarian cancer at the department during that period. Tumors with borderline malignancy were excluded. Ovarian tissue samples obtained from patients undergoing surgery for other than inflammatory or malignant conditions served as control (N 5 40). All included patients gave written consent for tissue use in research, and the study was approved by the local Institutional Ethics Review Board. Tissues were immediately frozen and either used for subsequent RNA extraction or stored at 2808C. To detect inactivating p53 mutations in ovarian cancer specimens, the functional yeast-based assay was used as previously described. 16 Clinicopathologic parameters of the training set are given in Table 1 . The unexpectedly high number of mucinous cancer specimens was chosen for adequate sample size in the subgroup analyses. Only mucinous cancer specimens with pathological review and proven ovarian origin were involved in the collective.
To validate the results from this training set two other collectives were defined: Validation set 1 includes 150 highgrade serous cancer specimens from the TCGA database. The cancer genome atlas (TCGA) data were analyzed using RNAseq V2 level 3 data for transcript isoforms (transcripts per million) from primary tumors (retrieved via Firebrowse (http://firebrowse.org/)) and clinical information including platinum resistance status as provided in the original publication. 17 Validation set 2 represents another 60 patients from
What's new?
Ovarian cancer is the most lethal gynecologic cancer in Western countries. Platinum resistance is a major obstacle for sufficient treatment, though understanding of the mechanisms involved in platinum resistance is incomplete. Our study shows that the N-terminal truncated Vav3.1 isoform, produced by alternative splicing of Vav3, a modulator of GTP hydrolases of the Rho/Rac family, is overexpressed in multi-drug resistant stem-cell like fractions of ovarian cancer cells. Vav3.1 expression was significantly higher in platinum-refractory ovarian cancers compared to other ovarian cancer specimens, with marked overexpression in ovarian tumors with genuine but not acquired platinum resistance.
our database. Clinicopathologic parameters of both validation sets are given in Supplementary Tables S1 and S2 .
Cell lines
HTB-77 and OVCAR-3 were purchased from ATCC (LGC Standards GmbH, Wesel, Germany), A2780 from Sigma (Sigma, Vienna, Austria) and IGROV-1 cells were a kind gift from Prof. R. Brown, London, UK. 18 Amplification of 15 STR-loci and the gender-specific locus amelogenin was carried out in the Institute of Legal Medicine, Medical University of Innsbruck, to authenticate these cell lines as described previously. 19 Whereas, the A2780 cell line exhibit wildtype TP53, OVCAR-3 and IGROV-1 cells contain deleterious TP53 mutations. 20 All cell lines were cultured in the appropriate medium (i.e., RPMI 1640, DMEM high glucose, MEM with Earle's Salts or Mc Coy's 5 A; all from PAA, Pasching, Austria) under standard conditions as published recently. 21 Human peritoneal mesothelial cells (HPMC) served as control and were obtained from patients undergoing surgery for other than inflammatory or malignant reasons. Cell preparation and culturing of HPMC were performed as published recently. 22 Flow cytometry and side population (SP) sorting Flow cytometry and cell sorting were performed on a FACSAria I (BD Biosciences, Vienna, Austria). Propidium iodide (eBioscience, Vienna, Austria) or 7-aminoactinomycin (BD Pharmingen, Vienna, Austria) staining was included in all staining protocols to discriminate viable from non-viable cells, and debris and doublets/aggregates were excluded based on FSC/SSC characteristics. Data were finally analyzed using FlowJo version 9.6 (Tree Star Software, Ashland, CA). SP sorting was performed as previously described. [23] [24] [25] Briefly, cells were adjusted to a concentration of 5 3 10 6 cells/mL culture medium and stained with 10 mM Vybrant V R DyeCycle TM Violet (DCV; Molecular Probes, Eugene, OR) for 90 min at 378C. Controls were incubated in the presence of 50 mM verapamil (Sigma-Aldrich, Vienna, Austria). Cells were washed in 103 volume ice-cold PBS (from PAA) and immediately flow sorted.
Gene array
Typically 500 ng/mL total RNA of SP (N 5 3) and the corresponding non-SP (N 5 3) fractions of A2780 cells were subjected to gene array analysis using the Affymetrix V R Human Gene 1.0 ST microarray platform. Hybridization and analysis was performed by the Applied Bioinformatics Group (Prof. R. Kofler, Division Molecular Pathophysiology, Medical University Innsbruck). The whole analysis was performed in R (http://www.r-project.org) using functions provided by Bioconductor packages. 26 The annotation of probe sets on the microarray to corresponding genes/transcripts bases on Ensembl database version 58 (http://www.ensembl.org). The RMA algorithm 27 was used for pre-processing of the raw microarray data. For definition of the probe sets the corresponding "CDF" (Chip Definition File) package from brainarray (http://brainarray.mbni.umich.edu) was used (Ensembl transcript version 13). 28 To assess the significance of differential expression of individual genes between sample groups, a moderated t-test was used (N 5 3).
RNA extraction and RT reaction
Total RNA was isolated from cell lines and patient samples using the RNeasy V R Mini Kit according to the manufacturer's Histopathologic grading of two patients was not available. 4 All patients received platinum-based adjuvant chemotherapy.
protocol (Qiagen, Hilden, Germany). Integrity was evaluated by assessing the 18 S-and 28-S-ribosomal RNA bands in 1% ethidium bromide-stained agarose gels, and reverse transcription was performed as described recently.
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Primers and probes
TaqMan V R Gene Expression Assays (AoD) Hs01041597_g1 for Vav1 (NM_005428.3) and Hs00610104_m1 for Vav2 (NM_001134398.1) were purchased from Applied Biosystems, Foster City, CA. Specific primers and probes for Vav3 isoforms alpha (NM_ 006113.4) and beta (AF_118886), 5
0 -truncated Vav3.1 (NM_001079874.1) and TATA box-binding protein (TBP; BT_019657) were designed using Primer Express Software v3.0.1 (Applied Biosystems). To prevent amplification of contaminating genomic DNA, forward primers were placed at a junction between two exons: Canonical Vav3-alpha between exons 18 b and 19, and Vav3.1 between exons 18a and 19. A common reverse primer and the probe were located in exon 20 and between exons 19 and 20, respectively. For Vav3-beta, the forward primer was located between unique exons 1 b and 3. In addition, an amplicon derived from the common 3 0 -sequence recognized all known Vav3 isoforms. Sequences of primers and probes are given in Supplementary Table S3 .
Real-time PCR amplification
RT-PCR was performed using an ABI Prism 7900 Detection System (Applied Biosystems, Foster City, CA) in a total volume of 25 mL reaction mixture containing 5 mL of each appropriately diluted RT sample (standard curve points and test samples), 12.5 mL TaqMan Universal PCR Master Mix (Applied Biosystems, Foster City, CA), 900 nM of each primer and 250 nM of the probe. Cycling conditions were an initial step at 508C for 2 min, a denaturing step at 958C for 10 min, and 45 cycles of 958C for 15 sec and 658C for 1 min. Real-time PCR efficacies were assessed by amplifying serially diluted cDNA isolated from the ovarian cancer cell line HTB-77. PCR assays were conducted in triplicates and the mean values were used for calculation. Only PCR experiments with detection efficiency over 95% were used for statistical analyses (R0 > 0.99). Gene expression levels were determined using the Comparative CT method according to User Bulletin 2 (Applied Biosystems, Foster City, CA). Levels of Vav isoform transcripts were normalized to TBP and given in absolute values in the text (arbitrary units, arb. units).
Immunoblotting
Cells were homogenized in a 50 mM Tris HCl buffer (pH 7.4) containing 5 mM EDTA-Tris, 50 mg/mL Aprotinin, 50 mg/mL Leupeptin, 2% (v/v) NP-40 5, mM Na-orthovanadate, 5 mM Na-pyrophosphate, 5 mM NaF, 50 mM NaCl. Protein lysates (75-175 mg) were separated on 12% SDSpolyacrylamide gels under reducing conditions, and transferred to polyvinylidene difluoride membranes (Millipore, Billerica, MA). Membranes were incubated with either the monoclonal rabbit anti-Vav3 antibody NB-EP1130Y (1:2000) (Novus Biologicals, Wisebaden-Nordenstadt, Germany) or with the mouse anti-a tubulin antibody B-5-1-2 (1:2,000). Membranes were washed and then incubated with goat antirabbit IgG (1:1,000) or with goat anti-mouse IgG (1:4,000) (Sigma-Aldrich); HRP activity was detected using enhanced chemiluminescence (ECL plus, Amersham Biosciences, Vienna, Austria).
Statistical analysis
Differences in expression level of Vav3 isoforms in SP and non-SP cells were evaluated by comparing the mean values from three independently performed experiments using Student's t-test. Differences between normal and malignant tissues and intergroup differences in clinicopathological characteristics were assessed using the Mann-Whitney U-test or the Kruskal-Wallis test. Data are expressed as median and interquartile range. The median was used for dichotomizing patients into two groups of high and low expression of Vav2 and Vav3 isoforms in all survival analyses. Univariate analyses were conducted for progression-free survival (PFS) and overall survival (OS) using the Kaplan-Meier estimator, and differences between groups were determined using the logrank test. To assess the predictive value of Vav2 and Vav3 isoform expression, a Cox proportional hazard model was used with adjustment for confounding variables. The final model included patients' age at diagnosis, FIGO stage, residual disease after primary debulking, cancer Type (Type-I vs. Type-II) and the levels of Vav isoform expression. SPSS for Windows 20.0 software (SPSS, Inc., Chicago, IL) was used for all analyses.
Results
Vav isoform expression in ovarian cancer cell lines and in HPMC
Expression levels of distinct Vav isoforms were analyzed in the three ovarian cancer cell lines OVCAR-3, IGROV-1, A2780, and in HPMC. At the transcriptome level Vav1, Vav2 and Vav3-beta were neither detectable in the ovarian cancer cell lines investigated, nor in HPMC. Although, Vav3-alpha and truncated Vav3.1 were also not detectable in HPMC, both isoforms were expressed in the three cancer cell lines investigated: Vav3.1 was the predominant isoform expressed in OVCAR-3 and IGROV-1 cells (mean: 6.52 6 0.44 and 63.55 6 6.74, respectively), whereas expression of canonical Vav3-alpha was low in both cell lines (mean: 0.52 6 0.01 and 0.20 6 0.06, respectively). In A2780 cells, expression of Vav3-alpha was clearly higher as compared to Vav3.1 (mean 1.80 6 0.08 vs. 0.13 6 0.01). These differences at the mRNA level were also verified at the protein level: a 98-kDa band corresponding to full-length Vav3-alpha was detected in A2780 cells, whereas the 33-kDa Vav3.1 specific band was nearly undetectable in this cell line. In OVACR-3 and IGROV-1 cells, however, Vav3.1 was observed at higher levels compared to the full-length Vav3 isoform alpha (Fig. 1a) .
None of the investigated ovarian cancer cell lines revealed Vav3-beta specific immunostaining (87 kDa).
Increased Vav3.1 expression in ovarian cancer stem cells
Recently, we postulated subsets of tumor cells within the ovarian cancer cell lines A2780 and IGROV1, which selectively express ABC transporter proteins resulting in a sidepopulation (SP) phenotype. 23 Purified SP cells exhibit typical stem-cell like properties such as clonogenicity, asymmetric division and tumorigenicity. Gene array analysis of stem-cell like SP and corresponding non-SP fractions (NSP) from A2780 cells obtained significant difference in expression for various genes, of which only seven met the threeway criterion of M 0.7, FDR 5 5% and p 0.05 (Figs. 1c  and 1d ). Within that gene panel, two genes, namely ABCB1 and Vav3, showed marked expression differences, whereas the other five candidate genes exhibited only moderate alterations. When distinct Vav3 isoforms were assessed at the transcriptome level in A2780, full-length Vav3-alpha revealed a twofold increase (p 5 0.021) and truncated Vav3.1 a ninefold increase (p 5 0.0001) in the SP-compared to NSP-cells. Due to low expression levels of Vav3-alpha in IGROV-1 cells, no difference in expression between SP and NSP was detectable; however, the SP fraction of IGROV1 showed a twofold overexpression of Vav3.1 (Fig. 1b) . At the protein level A2780 cells exhibited an increase in Vav3 isoform alpha immunoreactivity in the SP fraction compared to NSP. Despite the marked difference of Vav3.1 expression between SP and NSP at mRNA level, no Vav3.1 specific immunoreactivity could be detected in both A2780 fractions. However, the SP of IGROV-1 revealed an increase in Vav3.1 protein abundance compared to only a minor elevation of Vav3-alpha protein expression (Fig. 1a) . 
Vav expression in epithelial ovarian cancer specimens
To evaluate expression patterns of distinct Vav3 isoforms at protein level in primary ovarian cancer tissue, six tumor samples and two healthy controls were subjected to immunoblot analysis. As shown in Figure 2 , full-length Vav3-alpha immunoreactivity was detectable in all six samples at a variable amount. Three of the investigated samples (#1, #2 and #6) showed marked co-expression of the truncated isoform Vav3.1 at 33 kDa. In addition, we reproducibly detected an additional band at 130 kDa in all cancer specimens, which was absent in the investigated cell lines.
Interestingly, all tumor samples exhibiting co-expression of Vav3.1 were derived from high-grade serous ovarian cancers, and two of them (#1 and #6) turned out to be refractory to platinum-based treatment with OS rates of only 6 and 9 months, respectively. This tempted us to speculate on a potential clinical relevance of this truncated Vav3 isoform as biomarker for genuine platinum resistance. We therefore assessed the transcriptome levels of all known Vav isoforms in a large cohort of ovarian cancer patients.
As expected, Vav1 expression was not detectable in both the epithelial ovarian cancer and control samples (not shown). Even though, low level Vav2 expression was found in the cancer specimens (median 0.31 (0.02-0.85)), no significant correlation with clinicopathological parameters such as patients' age at diagnosis, FIGO stage, grading, histological subtype, residual disease after debulking surgery or platinumsensitivity could be disclosed.
Vav3-beta was not detectable in the entire collective, whereas canonical Vav3-alpha and Vav3.1 were expressed at low level in the control samples (median 0.52 and 0.48, respectively). In contrast, both isoforms were overexpressed in the tumor specimens with a 0.5-fold increase in Vav3-alpha (median 0.75 (0.47-1.27); p 5 0.003) and a marked 10-fold increase in Vav3.1 (median 4.52 (0.98-20.47); p 5 0.0001). Although, mRNA expression of both Vav3 isoforms was equally distributed among patients subdivided according to their age at diagnosis or histologic subtype, Vav3.1 but not Vav3-alpha expression showed a stepwise increase related to a higher FIGO stage (p 5 0.002; Supplementary Fig. S1 a) . As compared to grade I tumors, grades II and III specimens tended to express higher Vav3.1 levels, but did not reach statistical significance.
Finally, only Vav3.1 but not Vav3-alpha was significantly increased in patients exhibiting residual disease after primary debulking surgery compared to macroscopically complete tumor clearance (p 5 0.001; Supplementary Fig. S1b ).
Prognostic relevance of Vav2 and Vav3 expression in epithelial ovarian cancer
Neither full-length Vav3 nor Vav2 showed prognostic relevance regarding PFS or OS (Figs. 3a and 3b; Supplementary  Fig. 2 ).
In contrast, when patients were dichotomized according to Vav3. When patients were stratified according to the histological subtype into serous, mucinous and endometrioid cancers, high Vav3.1 expression was associated with poor PFS and OS only in the serous and in the endometrioid cancers. No association was detected in the subgroup of mucinous tumors ( Supplementary Fig. S3 ). This tempted us to speculate on differences in the prognostic impact of Vav 3.1 between Type-I and Type-II ovarian cancers. Classification between the two groups of ovarian cancers was performed in accordance to ref. [29] .
In 105 of the 150 tumors, the p53 mutational status was available and inactivating p53 mutations were detected in 70/ 105 (67.7%) of cancer specimens. In the high-grade serous ovarian cancers inactivating p53 mutations were detected in 96.8% of cancer specimens. Again, full-length Vav3 and Vav2 did not show prognostic relevance regarding PFS and OS in both subgroups. Interestingly, Vav3.1 levels above the median were associated with poor PFS and OS in Type-II but not in Type-I cancers (Figs. 4a-4d) . In Type-II cancers, the median time to progression was 15.0 (9.65-20.35) Of note, Vav3.1 was found to be an independent prognostic variable predicting both PFS and OS in the whole study cohort as well as in the Type-II cancers (Table 2) . From the other clinicopathologic parameters included in the model, only age at diagnosis and residual disease retained independent prognostic significance for both survival measures. .364), respectively). Even dichotomization in cancers exhibiting genuine (refractory) or acquired (resistant) platinum resistance revealed statistical significant difference between both groups (p 5 0.021). Within our collective, platinumrefractory ovarian cancer specimens exhibited a 30-fold overexpression of Vav3.1 as compared to healthy controls and a 13-fold Vav3.1 overexpression as compared to non-relapsing cancers and consequently very high platinum-sensitivity. Two independent data sets were established to validate the aforementioned findings (patient characteristics are given in Supplementary Tables S1 and S2). Validation set 1 consists of 150 high-grade serous ovarian cancers from the TCGA database. Within this collective, seven patients (4.9%) exhibit progressive disease (PD) during 1st line chemotherapy. Vav3.1 
Discussion
GTP hydrolases of the Rho/Rac family were shown to be involved in oncogenesis 2,31-33 and evidence emerged that its upstream regulators such as the Vav family of proteins could be either directly or indirectly involved in malignant transformation: involvement of Vav1 and Vav2 in tumorigenesis was shown in NSCLC, 34 oral squamous cell carcinoma (OSCC) 35 and in ductal carcinoma in situ with invasion of the breast. 36 Overexpression of Vav3 activates estrogen receptor signaling and is involved in breast carcinogenesis. 11, 12 Furthermore, Vav3 is associated with tumor progression, recurrence and AR activation in prostate cancer. 13, 37 However, most studies did not distinguish between different Vav3 isoforms and it is conceivable that structural alterations form a basis for the functional complexity in Vav3 dependent regulation. Herein, we evaluated the clinical impact of all known Vav family members in ovarian cancer and identified a marked difference between full-length Vav3-alpha and the N-terminal truncated isoform Vav3.1. In addition, based on our finding that Vav3.1 is overexpressed in ovarian cancer stem-cell like cells, it is tempting to speculate that Vav3 deregulation indicates a crucial step in ovarian cancer tumorigenesis, drug resistance and recurrence.
Both Vav1 and 2 are not expressed in ovarian cancer cell lines; Vav2 was shown to be expressed at very low levels in primary ovarian cancer samples, but not linked to biological variables or outcome. Vav3 was not detectable in HPMC and only at a very low level in the analyzed control samples, which is in line with earlier reports. 10 In contrast, mRNA expression of distinct Vav3 isoforms could be identified in all the ovarian cancer cell lines. In fact, Vav3-alpha and the truncated Vav3.1 isoform were inversely expressed in particular cell lines. High mRNA and protein expression of the truncated variant was linked to low levels of the full-length isoform (OVCAR-3 and IGROV-1). Vice versa, high expression of full-length Vav3-alpha was associated with low expression of Vav3.1 (A2780). At a first glance, a cell specific expression pattern of both isoforms would suggest that Vav3.1, which retains the 3 0 -SH3-SH2-SH3 domain only, may substitute the full-length isoforms in terms of functions mediated by that domain. However, it has been assumed that Vav3.1 modulates the activity of the full-length form and possibly other Vav pathways through competition. 9 The latter hypothesis is corroborated by the fact that both Vav3 isoforms were co-expressed in the cancer specimens. Finally, the SH3-SH2-SH3 domain present in Vav3.1 was shown to be functionally active by its own. 9 Considering our findings of Vav3.1 specific immunoreactivity in the absence of Vav3-alpha in IGROV-1 cells, it might be speculated that Vav3.1 could also exhibit unique and independent functions without regulatory influences of the N-terminal domains of the fulllength form. Indeed, artificial N-terminal truncation of Vav3 was shown to enhance membrane ruffle formation, an initial step during cell migration, and oncogenic activation. 38 Similar effects were observed after artificial deletion of the Nterminally located Ac and CH domains in Vav1 and Vav2. 39, 40 The exact role of Vav3.1 in the concert of Vav-dependent signaling is not yet fully elucidated and so far, available data would rather point to a reduced malignant potential of Vav3.1. Vav3.1 but not Vav3 was shown to be downregulated by transforming growth factor b (TGFb) or epidermal growth factor (EGF) in normal human epidermal keratinocytes and in the immortalized keratinocyte cell line HaCaT. 9 In addition, in locally advanced OSCC metastasized to regional lymph nodes, lower Vav3.1 mRNA levels were observed. 41 The herein presented clinical data are clearly different and would rather suggest a higher oncogenic potential of Vav3.1 as compared to full-length Vav3. This should at least be valid in ovarian cancer based on our findings: (i) Vav3.1 is 10-fold higher expressed compared to Vav3-alpha, which was found to be only slightly overexpressed in ovarian cancer specimens; (ii) Vav3.1 but not Vav3 highly correlated with peritoneal spread and residual disease after debulking surgery; (iii) Vav3.1 is selectively associated with poor clinical outcome and (iv) Vav3.1 has no prognostic impact in slow-growing Type-I, whereas in fast-growing Type-II ovarian cancers high expression is clearly linked to inferior outcome. To the best of our knowledge only one study discriminated between different Vav3 isoforms in cancer, 41 and we therefore cannot rule out that the oncogenic potential of Vav3.1 differs between distinct tumor entities. It might be hypothesized that in Vav3/Vav3.1 co-expressing cancers, a stronger competitor effect of the truncated isoform becomes important as was postulated by Trenkle et al. for OSCC. 41 However, in ovarian cancer specimens expression of Vav3.1 by far exceeded that of Vav3 (16-fold) and it is conceivable that Vav3.1 exhibits unique Vav3 independent functions in that tumor entity.
The concept of cancer stem cells crucially involved in tumorigenesis and recurrence of ovarian cancer has come into interest during the last decade. [42] [43] [44] Recently, we isolated subsets of tumor cells from different ovarian cancer cell lines exhibiting typical stem-cell like properties. 23 Gene array analyses revealed significant differences in expression of several genes, whereby two candidate genes, namely ABCB1 and Vav3, exhibited marked overexpression in the stem-cell like side-population. This finding is in line with a recent study showing that Vav3 is overexpressed in spheroid-forming ovarian cancer cell populations expressing stem cell markers such as ALDH1, CD44 and CD133. 45 In our study, Vav3 protein was shown to be associated with distant metastasis and poor clinical outcome in a collective of 74 cancer specimens. In our cohort full-length Vav3 was not associated with clinical outcome, whereas Vav3.1 overexpression was linked to clinicopathologically tumor variables and was also prognostically relevant. The presence of Vav3.1 protein in cancer specimens has not been identified so far, since available Vav3 specific antibodies bind either at the N-terminus outside the Vav3.1 specific sequence or at the common C-terminus. Therefore, protein data at present illustrate the expression of both Vav isoforms and the extrapolated clinicopathologic impact cannot be attributed to a distinct isoform. Consistently, our PCR amplicon derived from the common 3 0 -sequence and thus not distinguishing Vav3.1 and Vav3-alpha (designated as VAV3_all) also revealed prognostic relevance ( Supplementary Fig. S4 ).
SP fractions derived from ovarian cancer cell lines exhibited marked resistance to cytotoxic agents. 46, 47 Our clinical data demonstrate that exclusively platinum-refractory cancer specimens showed significantly increased Vav3.1 mRNA levels compared to all other cancers including fully platinum sensitive, PPS and even platinum resistant tumors. Although, administration of platinum is generally associated with high rates of clinical responses, drug exposure can lead to an adaptive response rendering malignant cells less platinumsusceptible over time. 48, 49 In contrast, the fraction of platinum-refractory ovarian cancers is assumed to be a priori multi-drug resistant in clinical practice. Thus, it is tempting to speculate that this subgroup of ovarian cancers represents a unique fraction of tumors, which is corroborated by the fact of the selective Vav3.1 overexpression as seen in our collective. However, the exact mechanisms underlying genuine drug resistance in ovarian cancer is far from being fully understood. It might be hypothesized that cancers exhibiting intrinsic chemo-resistance such as platinum-refractory ovarian cancers may contain larger populations of multi-drug resistant stem-cells and that within these tumor specimens higher levels of MDR proteins contribute to the underlying mechanism. However, a more direct involvement of Vav3.1 in chemo-resistance pathways cannot be entirely ruled out. Recent data showed that knock-down of Vav3 sensitizes paclitaxel (PTX)-resistant cancer cells to PTX treatment. 47 In addition, siRNA-based downregulation of Vav3 yields a significant decrease in MDR1/P-gp, GST-p, Bcl-2 and Bax expression in gastric cancer cells. 50 In conclusion, we herein demonstrate for the first time that truncated Vav3.1 and not full-length isoform of Vav3, is clinically relevant in the pathophysiology of ovarian cancer. Importantly, Vav3.1 also appears to be decisively involved in mechanisms causing intrinsic drug resistance. This potentially enables Vav3.1 to serve as an early and suitable biomarker to predict chemo-sensitivity of the individual cancer, hence contributing to refine decision making and personalized treatment planning in ovarian cancer.
